Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua W D Tobin

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Internal Medicine Journal|August 5, 2024
Diagnosis, management and follow-up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma AllianceJoshua W D Tobin, Greg Hapgood, Anna Johnston, et al.
Internal Medicine Journal|October 20, 2021
Diagnosis, management and follow up of peripheral T-cell lymphomas: a consensus practice statement from the Australasian Lymphoma AllianceGreg Hapgood, Maya Latimer, Sze Ting Lee, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 4, 2021
Successful treatment of Epstein-Barr virus-associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein-Barr virus-specific T cellsSoi C Law, Thanh Hoang, Kacey O'Rourke, et al.
Blood Advances|June 22, 2021
Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphomaKarthik Nath, Soi-Cheng Law, Muhammed B Sabdia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2019
Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune InfiltrationJoshua W D Tobin, Colm Keane, Jay Gunawardana, et al.
Hemasphere|October 15, 2021
Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma AllianceStephen Boyle, Joshua W D Tobin, Jacinta Perram, et al.
Blood Neoplasia|June 24, 2025
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapyJoshua W D Tobin, Venkata A Chikatamarla, Marko Matic, et al.
American Journal of Hematology|August 17, 2024
Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphomaJay Gunawardana, Soi C Law, Muhammed B Sabdia, et al.
Blood Advances|October 2, 2019
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma AllianceJoshua W D Tobin, Gabrielle Rule, Katherine Colvin, et al.
Ebiomedicine|December 4, 2024
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphomaMichael P MacManus, John F Seymour, Hennes Tsang, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Internal Medicine Journal|August 5, 2024
Diagnosis, management and follow-up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma AllianceJoshua W D Tobin, Greg Hapgood, Anna Johnston, et al.
Internal Medicine Journal|October 20, 2021
Diagnosis, management and follow up of peripheral T-cell lymphomas: a consensus practice statement from the Australasian Lymphoma AllianceGreg Hapgood, Maya Latimer, Sze Ting Lee, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 4, 2021
Successful treatment of Epstein-Barr virus-associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein-Barr virus-specific T cellsSoi C Law, Thanh Hoang, Kacey O'Rourke, et al.
Blood Advances|June 22, 2021
Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphomaKarthik Nath, Soi-Cheng Law, Muhammed B Sabdia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2019
Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune InfiltrationJoshua W D Tobin, Colm Keane, Jay Gunawardana, et al.
Hemasphere|October 15, 2021
Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma AllianceStephen Boyle, Joshua W D Tobin, Jacinta Perram, et al.
Blood Neoplasia|June 24, 2025
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapyJoshua W D Tobin, Venkata A Chikatamarla, Marko Matic, et al.
American Journal of Hematology|August 17, 2024
Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphomaJay Gunawardana, Soi C Law, Muhammed B Sabdia, et al.
Blood Advances|October 2, 2019
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma AllianceJoshua W D Tobin, Gabrielle Rule, Katherine Colvin, et al.
Ebiomedicine|December 4, 2024
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphomaMichael P MacManus, John F Seymour, Hennes Tsang, et al.
Pageof 3